JP2009515553A5 - - Google Patents

Download PDF

Info

Publication number
JP2009515553A5
JP2009515553A5 JP2008541268A JP2008541268A JP2009515553A5 JP 2009515553 A5 JP2009515553 A5 JP 2009515553A5 JP 2008541268 A JP2008541268 A JP 2008541268A JP 2008541268 A JP2008541268 A JP 2008541268A JP 2009515553 A5 JP2009515553 A5 JP 2009515553A5
Authority
JP
Japan
Prior art keywords
test kit
cells
solution
vegfr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008541268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009515553A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/044117 external-priority patent/WO2007059094A2/en
Publication of JP2009515553A publication Critical patent/JP2009515553A/ja
Publication of JP2009515553A5 publication Critical patent/JP2009515553A5/ja
Pending legal-status Critical Current

Links

JP2008541268A 2005-11-14 2006-11-14 癌の予知および予後と、癌治療のモニタリング Pending JP2009515553A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73585405P 2005-11-14 2005-11-14
PCT/US2006/044117 WO2007059094A2 (en) 2005-11-14 2006-11-14 Methods for prediction and prognosis of cancer, and monitoring cancer therapy

Publications (2)

Publication Number Publication Date
JP2009515553A JP2009515553A (ja) 2009-04-16
JP2009515553A5 true JP2009515553A5 (https=) 2009-12-10

Family

ID=37814675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008541268A Pending JP2009515553A (ja) 2005-11-14 2006-11-14 癌の予知および予後と、癌治療のモニタリング

Country Status (12)

Country Link
US (1) US20070178494A1 (https=)
EP (1) EP1963849A2 (https=)
JP (1) JP2009515553A (https=)
KR (1) KR20080073745A (https=)
CN (1) CN101454668A (https=)
AU (1) AU2006315592A1 (https=)
BR (1) BRPI0618597A2 (https=)
CA (1) CA2629860A1 (https=)
MX (1) MX2008006239A (https=)
RU (1) RU2008123406A (https=)
WO (1) WO2007059094A2 (https=)
ZA (1) ZA200804509B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
SG160364A1 (en) * 2005-03-07 2010-04-29 Bayer Schering Pharma Ag Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
BRPI0617488A2 (pt) * 2005-10-21 2011-07-26 Bayer Healthcare Llc mÉtodo para a monitoraÇço do estado de uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente, mÉtodo de seleÇço de terapia para um paciente humano com uma doenÇa e mÉtodo de dignàstico para detectar uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente
CA2628091A1 (en) * 2005-11-02 2007-05-18 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US20100008910A1 (en) * 2006-09-12 2010-01-14 John Chant Methods and compositions for the diagnosis and treatment of cancer
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US20100311106A1 (en) * 2008-01-25 2010-12-09 Hartmann Lynn C Quantitation of lobular involution for breast cancer risk prediction
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
JP5439494B2 (ja) * 2008-10-21 2014-03-12 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
BR112012007762A2 (pt) * 2009-10-07 2021-11-16 Koninklijke Philips Electronics Nv Método de avaliação do nível de toxicidade de um paciente que se submete a um protocolo de tratamento de câncer, produto de programa de computador, sistema (200) para avaliar o nível de toxicidade de um paciente que se submete a um protocolo de tratamento de câncer
CN102053150B (zh) * 2009-10-30 2013-07-17 上海交通大学医学院附属瑞金医院 一种人成骨肉瘤干细胞相关抗原标记物及其应用
AU2011281706A1 (en) * 2010-07-19 2013-01-10 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
EP2601528B1 (en) * 2010-08-02 2015-10-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel methods for predicting the responsiveness of a patient affected with a tumor to a treatment with a tyrosine kinase inhibitor
WO2012081898A2 (ko) 2010-12-13 2012-06-21 사회복지법인 삼성생명공익재단 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
DK3141617T3 (en) * 2011-01-11 2019-02-25 Inst Nat Sante Rech Med PROCEDURE FOR PREVENTING THE CANCER OF A CANCER ON A PATIENT BY ANALYZING GENEPRESSION
WO2013173384A1 (en) * 2012-05-16 2013-11-21 Dale Wong Method and system for sorting biological samples
EP2971101A2 (en) * 2013-03-15 2016-01-20 Janssen Pharmaceutica N.V. Assay for predictive biomarkers
US10017823B2 (en) * 2013-04-25 2018-07-10 Cbs Bioscience, Co., Ltd Analytical method for increasing susceptibility of molecular targeted therapy in hepatocellular carcinoma
RU2546035C1 (ru) * 2014-04-15 2015-04-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования развития метастазов у больных меланомой кожи
RU2643761C1 (ru) * 2017-08-10 2018-02-05 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ расчета прогноза раннего прогрессирования меланомы кожи
WO2019074920A1 (en) * 2017-10-10 2019-04-18 Oncocyte Corporation METHODS AND COMPOSITIONS FOR THE DETECTION AND DIAGNOSIS OF BREAST CANCER

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635421B1 (en) * 1997-12-09 2003-10-21 Children's Medical Center Corporation Neuropilins and use thereof in methods for diagnosis and prognosis of cancer
US20030232400A1 (en) * 2002-12-20 2003-12-18 Susan Radka Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome
WO2005009367A2 (en) * 2003-07-17 2005-02-03 Ambit Biosciences Corporation Treatment of diseases with kinase inhibitors
BRPI0508970A (pt) * 2004-03-19 2007-08-21 Penn State Res Found método combinatórios e composições para o tratamento de melanoma

Similar Documents

Publication Publication Date Title
JP2009515553A5 (https=)
Wang et al. Detection of SARS-CoV-2 and its mutated variants via CRISPR-Cas13-based transcription amplification
Le et al. Dual recognition element lateral flow assay toward multiplex strain specific influenza virus detection
ES2540108T3 (es) Marcadores en la orina para la detección del cáncer de vejiga
Tainsky Genomic and proteomic biomarkers for cancer: a multitude of opportunities
US20110301046A1 (en) Methods of Determining Efficacy of Glucocorticoid Treatment of Eosinophilic Esophagitis
JP2007525661A5 (https=)
JP2011528903A5 (https=)
JP2012526554A5 (https=)
JP2010536372A5 (https=)
JP2019500582A5 (https=)
FI2398902T3 (fi) Menetelmiä ja koostumuksia syövän diagnoosia ja hoitoa varten
JP2013178260A5 (https=)
DE602005011008D1 (de) Verwendung der Gene Kir2.3 und DRD2 als molekulare Marker zur Diagnose von Schizophrenie
JP2010521655A5 (https=)
US12195795B2 (en) Synthetic strands for nucleic acid sequencing and related methods and systems
Saber et al. Lack of acute phase response in the livers of mice exposed to diesel exhaust particles or carbon black by inhalation
EP4237850A1 (en) Improved assays to quantify chromatin targets using antibody-targeted enzyme digestion
JP2022515221A (ja) クロマチンマッピングアッセイ用のdnaバーコード化ヌクレオソーム
Pereira et al. Enlarging the toolbox against antimicrobial resistance: aptamers and CRISPR-Cas
JP2011519030A5 (https=)
Roth et al. Rapid biosensing method for detecting protein–DNA interactions
Khoshbin et al. A CRISPR/Cas12a-powered liquid crystal aptasensor for point-of-care detection of prostate-specific antigen for early-stage cancer diagnosis
Yahyavi et al. Nucleic acid‐based electrochemical biosensor for detection of influenza B by gold nanoparticles
JP2008547006A5 (https=)